| Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study M Augustin, P Schommers, M Stecher, F Dewald, L Gieselmann, H Gruell, ... The Lancet Regional Health – Europe 6, 100122, 2021 | 646 | 2021 |
| HIV therapy by a combination of broadly neutralizing antibodies in humanized mice F Klein, A Halper-Stromberg, JA Horwitz, H Gruell, JF Scheid, ... Nature 492, 118-122, 2012 | 576 | 2012 |
| Combination therapy with anti-HIV-1 antibodies maintains viral suppression P Mendoza, H Gruell, L Nogueira, JA Pai, AL Butler, K Millard, ... Nature 561, 479-484, 2018 | 458 | 2018 |
| SARS‐CoV‐2 targets neurons of 3D human brain organoids A Ramani, L Müller, PN Ostermann, E Gabriel, P Abida‐Islam, ... The EMBO Journal 39, e106230, 2020 | 453 | 2020 |
| Antibody 10-1074 suppresses viremia in HIV-1-infected individuals M Caskey, T Schoofs, H Gruell, A Settler, T Karagounis, EF Kreider, ... Nature Medicine 23, 185-191, 2017 | 448 | 2017 |
| mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant H Gruell, K Vanshylla, P Tober-Lau, D Hillus, P Schommers, C Lehmann, ... Nature Medicine 28, 477-480, 2022 | 403 | 2022 |
| Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients C Kreer, M Zehner, T Weber, MS Ercanoglu, L Gieselmann, C Rohde, ... Cell 182, 843-854.e12, 2020 | 369 | 2020 |
| Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study D Hillus, T Schwarz, P Tober-Lau, K Vanshylla, H Hastor, C Thibeault, ... The Lancet Respiratory Medicine 9, 1255-1265, 2021 | 347 | 2021 |
| Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals Y Bar-On, H Gruell, T Schoofs, JA Pai, L Nogueira, AL Butler, K Millard, ... Nature Medicine 24, 1701-1707, 2018 | 226 | 2018 |
| Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans K Vanshylla, V Di Cristanziano, F Kleipass, F Dewald, P Schommers, ... Cell Host & Microbe 29, 917-929.e4, 2021 | 158 | 2021 |
| Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity J Niessl, AE Baxter, P Mendoza, M Jankovic, YZ Cohen, AL Butler, CL Lu, ... Nature Medicine 26, 222-227, 2020 | 117 | 2020 |
| Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19 SJ Theobald, A Simonis, T Georgomanolis, C Kreer, M Zehner, HS Eisfeld, ... EMBO Molecular Medicine 13, e14150, 2021 | 115 | 2021 |
| Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV SA Ehrhardt, M Zehner, V Krähling, H Cohen-Dvashi, C Kreer, N Elad, ... Nature Medicine 25, 1589-1600, 2019 | 105 | 2019 |
| Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody P Schommers, H Gruell, ME Abernathy, MK Tran, AS Dingens, HB Gristick, ... Cell 180, 471-489.e22, 2020 | 102 | 2020 |
| A mouse model for HIV-1 entry J Pietzsch, H Gruell, S Bournazos, BM Donovan, F Klein, R Diskin, ... Proceedings of the National Academy of Sciences 109, 15859-15864, 2012 | 90 | 2012 |
| Broad and potent neutralizing antibodies recognize the silent face of the HIV envelope T Schoofs, CO Barnes, N Suh-Toma, J Golijanin, P Schommers, H Gruell, ... Immunity 50, 1513-1529.e9, 2019 | 87 | 2019 |
| Antibody-Mediated Neutralization of SARS-CoV-2 H Gruell, K Vanshylla, T Weber, CO Barnes, C Kreer, F Klein Immunity 55, 925-944, 2022 | 81 | 2022 |
| Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption CL Lu, JA Pai, L Nogueira, P Mendoza, H Gruell, TY Oliveira, J Barton, ... Proceedings of the National Academy of Sciences 115, E11341-E11348, 2018 | 73 | 2018 |
| Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers P Tober-Lau, T Schwarz, K Vanshylla, D Hillus, H Gruell, N Suttorp, ... The Lancet Respiratory Medicine 9, e104-e105, 2021 | 72 | 2021 |
| Antibody-mediated prevention and treatment of HIV-1 infection H Gruell, F Klein Retrovirology 15, 73, 2018 | 71 | 2018 |
